Amarin Reports Strong International Demand and Improved Financials in Q2 Earnings Call
In its second-quarter earnings call, Amarin Corporation PLC (NASDAQ:AMRN) highlighted strong international demand for VASCEPA. Global in-market demand rose by 59% year-over-year, with European demand increasing by 69%. The drug is now available in 22 countries and supported internationally through partnerships like Recordati in Europe. Despite these gains, U.S. sales faced challenges due to generic competition and pricing pressure, leading to a decline in product revenue to $32.2 million. However, Amarin's financial position improved significantly with operating expenses dropping by 59% to $27 million and cash reserves rising to $314.6 million. Management described the quarter as an inflection point following restructuring efforts that reduced costs and positioned the company for sustainable growth.
Tickers: $AMRN
Topics: financial performance international expansion pharmaceuticals